Vyome Holdings Management
Management criteria checks 1/4
Vyome Holdings' CEO is N. Venkat Nelabhotla, appointed in Aug 2025, has a tenure of 1.08 years. total yearly compensation is $478.71K, comprised of 54.3% salary and 45.7% bonuses, including company stock and options. directly owns 0% of the company’s shares, worth $15.90. The average tenure of the management team and the board of directors is 1 years and 1.1 years respectively.
Key information
N. Venkat Nelabhotla
Chief executive officer
US$478.7k
Total compensation
| CEO salary percentage | 54.31% |
| CEO tenure | 1.1yrs |
| CEO ownership | 0.0001% |
| Management average tenure | 1yr |
| Board average tenure | 1.1yrs |
Recent management updates
Recent updates
HIND: New Finance Leadership Will Support Future Earnings Multiple Expansion
Analysts have adjusted their price target on Vyome Holdings to $8.83 from $11.50, reflecting updated assumptions for revenue growth, profit margins and future P/E expectations. What’s in the News for Vyome Holdings Vyome Holdings appointed Jerry Leonard as Chief Financial Officer, effective September 1, 2026, following board approval on August 27, 2026.Rare Disease And Immuno Inflammatory Pipeline Will Drive Long Term Upside Potential
Catalysts About Vyome Holdings Vyome Holdings focuses on immuno-inflammatory and rare disease therapeutics with lead asset VT-1953 for malignant fungating wounds. What are the underlying business or industry changes driving this perspective?CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$11m |
| Mar 31 2026 | n/a | n/a | -US$11m |
| Dec 31 2025 | US$479k | US$260k | -US$10m |
Compensation vs Market: N. Venkat's total compensation ($USD478.71K) is about average for companies of similar size in the US market ($USD652.98K).
Compensation vs Earnings: Insufficient data to compare N. Venkat's compensation with company performance.
CEO
N. Venkat Nelabhotla (64 yo)
Mr. Venkateswarlu Nelabhotla, also known as N. Venkat, MBA, is a Co-Founder of Vyome Holdings, Inc. (formerly known as Vyome Biosciences Private Limited). Mr. Nelabhotla serves as President and Chief Execu...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 1.1yrs | US$478.71k | 0.00011% $ 15.9 | |
| Co-Founder | no data | no data | 0.0013% $ 189.4 | |
| CFO, Principal Financial & Accounting Officer | no data | no data | no data | |
| Chief Technology Officer | 1yr | no data | no data | |
| Investor Relations Officer | no data | no data | no data | |
| Senior Vice President of Product Development & Regulatory CMC | 8.8yrs | no data | no data | |
| Senior Vice President of Clinical Development | 1yr | no data | no data |
Experienced Management: HIND's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | no data | US$478.71k | 0.00011% $ 15.9 | |
| Co-Founder | 1.1yrs | no data | 0.0013% $ 189.4 | |
| Independent Director | 1.1yrs | no data | no data | |
| Member of Scientific and Clinical Advisory Board | no data | no data | no data | |
| Member of Scientific and Clinical Advisory Board | no data | no data | no data | |
| Member of Scientific and Clinical Advisory Board | no data | no data | no data | |
| Member of Scientific and Clinical Advisory Board | no data | no data | no data | |
| Independent Chairman | 1.1yrs | no data | 0.0029% $ 412.1 | |
| Member of Scientific and Clinical Advisory Board | no data | no data | no data | |
| Co-Founder & Member of Scientific and Clinical Advisory Board | no data | no data | no data | |
| Member of Scientific and Clinical Advisory Board | no data | no data | no data | |
| Independent Director | 1.1yrs | no data | no data |
Experienced Board: HIND's board of directors are not considered experienced ( 1.1 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/14 22:10 |
| End of Day Share Price | 2026/09/14 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vyome Holdings, Inc. is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Keay Nakae | Chardan Capital Markets, LLC |
| Theodore O'Neill | Litchfield Hills Research, LLC |
| Jason McCarthy | Maxim Group |